Safety

Vyvanse (lisdexamfetamine dimesylate) Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

January 2015

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • …constipation…
     

 

July 2014

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Bruxism

 

December 2013

Summary View

ADVERSE REACTIONS

  • frequent or prolonged erections 

 

September 2011

Summary View

ADVERSE REACTIONS

Postmarketing Reports
  • Psychiatric Disorder: dermatillomania

 

November 2010

Summary View

PRECAUTIONS

Drug Interactions
Agents Whose Blood Levels May be Impacted by Vyvanse
  • Extended release guanfacine: In a drug interaction study (N=40), administration of an extended release guanfacine (4 mg) in combination with Vyvanse (50mg) increased guanfacine maximum plasma concentration=by 19%, whereas, exposure (area under the curve; AUC) was increased by 7%. These small changes are not expected to be clinically meaningful. In this study, no effect on d-amphetamine exposure was observed following co-administration of extended release guanfacine and Vyvanse.

ADVERSE REACTIONS

Postmarketing Reports
Immune System Disorders: anaphylactic reaction
 

 

Page Last Updated: 02/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.